Not FDA-approved
Immune & defense
Thymosin alpha-1
Evidence
Approved in some countries, not the U.S.
Class
28-amino-acid thymic peptide
KEY TAKEAWAY
Thymosin alpha-1 is a peptide first isolated from the thymus gland. It is approved in some countries as an immune modulator for hepatitis and as a vaccine adjunct, but it is not approved by the FDA.
Written by the Veylo editorial team · Updated
November 2026
What it is
A thymus-derived peptide that modulates immune activity
Studied for
Hepatitis B and C, vaccine response and severe infections
Key fact
Used as a drug in several countries; trial results are mixed
Route
Injection
Evidence strength
Approved in some countries, not the U.S.
Thymosin alpha-1, also called thymalfasin, is a synthetic version of a peptide produced in the thymus.
It appears to stimulate T cells and dendritic cells, helping the immune system respond to infection and vaccines.
Approved in several countries outside the U.S. under the name Zadaxin. It has no FDA approval.
Used in some countries for chronic hepatitis B and C and as an adjunct to vaccines in older or immunocompromised patients. Studied in sepsis with mixed results.
Injection-site reactions are the most commonly reported effect. Serious adverse events were uncommon in trials.
Primary literature for this entry is being compiled.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.